Preclinical studies have shown that ET-0038 is highly effective in inhibiting SHP2 activity in a variety of tumor models in vitro and in vivo that carry carcinogenic mutations in the RTK/RAS pathway, resulting in significant antitumor activity. This evidence concerns the gene PTPN11 and neoplasm.